Author:
Chinn Megan M.,Mateos Diego Lopez,Riley Mary A.,Siegel Justin B.
Abstract
ABSTRACTAlzheimer’s disease is the most common form of dementia affecting 35 million people globally. One of the major efforts in the development of a treatment for Alzheimer’s is to reduce the rate of plaque formation, the common hallmark of Alzheimer’s disease. The protease BACE-1 has been demonstrated to play a role in catalyzing plaque formation and is therefore a major drug target. Here we report potential new drug candidates building upon Verubecestat, developed through computationally driven molecular modeling methods. Both designed molecules have improved docking scores relative to Verubecestat when modeled in the BACE-1 active site, and therefore present potential new leads for more effective therapeutics to combat Alzheimer’s disease.
Publisher
Cold Spring Harbor Laboratory
Reference20 articles.
1. A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment;CNS Drugs,2019
2. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
3. Fujimoto, K. ; Yoshida, S. ; Tadano, G. ; Asada, N. ; Fuchino, K. ; Suzuki, S. ; Matsuoka, E. ; Yamamoto, T. ; Yamamoto, S. ; Ando, S. ; Kanegawa, N. ; Tonomura, Y. ; Ito, H. ; Moechars, D. ; Rombouts, F. ; Gijsen, H. ; Kusakabe, K. Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2. J Med Chem. 2021, 64 (6).
4. Luo, X. ; Yan, R. Inhibition of BACE1 for therapeutic use in alzheimer’s disease. International journal of clinical and experimental pathology. 2010, 3 (6).
5. BACE1 and BACE2 enzymatic activities in Alzheimer’s disease